MELD Calculator vs myFibroScan

Explore MELD scores and regional liver transplant data with MELD Calc, an educational reference for healthcare professionals, trainees, and students. Calculate and compare Original MELD, MELD-Na, and MELD 3.0 scores in one place. Enter laboratory values, adjust dialysis and sex inputs, and see results update as you explore different scenarios. Features include: • Side-by-side Original MELD, MELD-Na, and MELD 3.0 results. • Model-based estimates of 30-, 60-, and 90-day survival and mortality for educational reference. • NEW: An interactive heat map of Median MELD at Transplant (MMaT) data by donor hospital. • Hospital search and regional comparisons. • A Time Machine feature to explore historical MMaT cohorts beginning in June 2022. • In-app references to published research and OPTN source information. • Light and dark mode support. Whether you’re studying MELD scoring or exploring geographic differences in transplant data, MELD Calc brings calculations and visual context together in a simple interface. For educational and reference purposes only. MELD Calc is not a clinical tool and must not be used to make decisions about patient care, diagnosis, treatment, or transplant eligibility. Estimates do not predict individual outcomes. Always consult qualified healthcare professionals and current institutional protocols for patient management.

FibroScan® is the non-invasive gold standard solution for comprehensive management of liver health. FibroScan® is powered by three unique, patented and validated biomarkers, LSM by VCTE™ (Liver Stiffness Measurement) and CAP™ (Controlled Attenuation Parameter) that benefit from a worldwide clinical evidence with over 5300+ peer-reviewed publications and 180+ international guidelines. myFibroScan app is your everyday FibroScan® companion to access Interpretation Guide and FibroScan® based scores in an easy, fast and intuitive way : The Interpretation Guide utilizes data from clinical studies to assist providers in interpreting FibroScan® examination results. Scores enhance FibroScan® liver disease assessment with biological markers. Scores are presented as educational services intended for licensed healthcare professionals. While the scores are about specific medical and healthcare issues, they are not a substitute for/or replacement of personalized medical advice and are not intended to be used as the sole basis for making individualized medical or health-related decisions. • Fast is an aid to identify at risk MASH patients defined as MASH + NAS≥4 + F≥2. Good to excellent performance in cohorts from different clinical settings (MASLD tertiary care unit, screening, bariatric surgery) and geographical origins (USA, Europe, Asia). Several publications advocate the use of Fast. • Agile 3+ is an aid to identify MASLD patients with advanced fibrosis by combining LSM by VCTE™ and routine clinical parameters to reduce the need for liver biopsy. High clinical performances are demonstrated in large external validation cohorts from different geographical origins. • Agile 4 is an aid to early identify MASLD patients with cirrhosis by combining LSM by VCTE™ and routine clinical parameters. It can help the physicians to manage the disease to prevent liver-related complications such as hepatocellular carcinoma. High clinical performances are demonstrated in large external validation cohorts from different geographical origin. MASH Treatment Eligibility Tool to eliminate the Guesswork. This patient management tool embeds treatment recommendations based on the patient’s FibroScan® results and the latest AASLD Guidance.